Almost all the treatments that are currently being carried out at the clinic are based on somatic stem cells while there is still a huge potential to unlock for the use of pluripotent cells which can differentiate into almost all types of tissues. Allogenic treatments can be generated from pluripotent stem cells obtained from embryos not used for reproductive purposes while autologous treatments come from patient’s cells reprogrammed into iPSCs. Both types of treatment have advantages and disadvantages. While allogeneic treatment has the advantage of immediacy, it has the disadvantage of possible rejections, autologous avoid rejection but make it impossible for off-the-shelf product. From the experimental development point of view, it is necessary to promote the expansion of cells in GMP environments and protocolize new methods of expansion/differentiation of specific cells for specific diseases but also generic to obtain ready-to-use products.
ADVANCE(CAT) intends to promote the use of somatic stem cells towards clinical application and industrial exploitation. Further, ADVANCE(CAT) works on the potential of pluripotent stem cells, both PSCs and ESCs, for specific diseases.